Hologic, Inc. revised earnings guidance for the Fiscal year 2023. For the year, the Company expects revenues of $3,850 million to $4,000 million compared to previous guidance of $3,700 million to $3,900 million and GAAP EPS of $2.69 to $2.99 compared to previous guidance of $2.51 to $2.81.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.99 USD | -1.10% | -1.16% | +3.55% |
05-22 | FDA classifies recall of Hologic's implant as 'most serious' | RE |
05-22 | FDA classifies recall of Hologic's implants for soft tissue as 'most serious' | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.55% | 17.46B | |
+10.22% | 226B | |
+12.99% | 198B | |
+18.09% | 142B | |
+28.66% | 111B | |
+2.09% | 65.26B | |
+14.70% | 54.36B | |
+6.68% | 50.94B | |
+8.29% | 44.8B | |
+2.60% | 36.8B |
- Stock Market
- Equities
- HOLX Stock
- News Hologic, Inc.
- Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023